Miles Morris
Contributed toward testing novel lentiviral and AAV plasmids.
NOTCH3-related disease
CADASIL is a genetic cerebral small vessel disease with urgent therapeutic need.
CADASIL is commonly caused by pathogenic variants in the NOTCH3 gene. It affects small blood vessels in the brain and can lead to migraine with aura, strokes, cognitive changes, mood symptoms, and progressive disability.
Research focus
From NOTCH3 biology to testable gene-targeted therapies.
NOTCH3 pathogenic variants provide a precise biological starting point for CADASIL therapeutic research. The project focuses on experimental systems that can test whether candidate interventions change disease-relevant vascular readouts.
This space links software-enabled design, plasmid and vector testing, ASO concepts, and practical translational questions around delivery, safety, and measurable benefit.
Project leadership
Dr Favour Felix-Ilemhenbhio leads the CADASIL therapeutic testing space.
Dr Felix-Ilemhenbhio develops and tests gene-targeted strategies for NOTCH3-related disease, with a focus on therapeutic design, plasmid and vector testing, and antisense oligonucleotide approaches that can be evaluated in disease-relevant experimental systems.
This space is shaped by the need to move carefully from design to evidence: building tools, testing measurable vascular readouts, and identifying which therapeutic concepts have enough biological promise to justify further translational development.
People and projects
The NOTCH3 therapeutic testing space.
Dr Favour Felix-Ilemhenbhio leads this area, with student contributions supporting experimental testing of novel therapeutic concepts for NOTCH3-related disease.
Alanur Ciger
Contributed toward testing antisense oligonucleotide approaches.
Family-facing science
Understanding CADASIL through genetics, symptoms, and therapeutic readiness.
This page brings together what families and collaborators need to understand: the role of NOTCH3, the clinical features of CADASIL, and the research steps needed before a therapy can be responsibly tested.
Future additions can include diagnosis basics, symptom management, family genetics, clinical trial updates, and questions to bring to clinicians.
